JBC Ideal method for primary cell transfection

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leissring, M. A.
Right arrow Articles by LaFerla, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leissring, M. A.
Right arrow Articles by LaFerla, F. M.

J Biol Chem, Vol. 274, Issue 46, 32535-32538, November 12, 1999

COMMUNICATION
Presenilin-2 Mutations Modulate Amplitude and Kinetics of Inositol 1,4,5-Trisphosphate-mediated Calcium Signals*

Malcolm A. LeissringDagger §, Ian Parkerparallel , and Frank M. LaFerlaDagger §**

From the Laboratories of Dagger  Molecular Neuropathogenesis and parallel  Cellular and Molecular Neurobiology, Department of Neurobiology and Behavior, § Center for the Neurobiology of Learning and Memory,  Institute for Brain Aging and Dementia, University of California, Irvine, California 92697-4545

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mutations in the two presenilin genes (PS1, PS2) account for the majority of early-onset familial Alzheimer's disease (FAD) cases. Converging evidence from a variety of experimental systems, including fibroblasts from FAD patients and transgenic animals, indicates that PS1 mutations modulate intracellular calcium signaling pathways. Despite the potential relevance of these changes to the pathogenesis of FAD, a comparable effect for PS2 has not yet been demonstrated experimentally. We examined the effects of wild-type PS2, and both of the identified FAD mutations in PS2, on intracellular calcium signaling in Xenopus oocytes. Inositol 1,4,5-trisphosphate (IP3)-evoked calcium signals were significantly potentiated in cells expressing either of the PS2 mutations relative to wild-type PS2-expressing cells and controls. Decay rates of calcium signals were also significantly accelerated in mutant PS2-expressing cells in a manner dependent upon IP3 concentration. The finding that mutations in both PS1 and PS2 modulate intracellular calcium signaling suggests that these disturbances may represent a common pathogenic mechanism of presenilin-associated FAD.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Most cases of familial Alzheimer's disease (FAD)1 are linked to mutations in two related genes, presenilin-1 and presenilin-2 (PS1, PS2) (1). These genes, which diverged from a single ancestor, share a similar genomic organization and encode proteins that are 67% identical. PS1 and PS2 are multipass, integral membrane proteins localized predominantly to the endoplasmic reticulum (ER) (2, 3) and are widely expressed throughout the brain (4). Despite their similarities, there are genetic and physiological differences between these two molecules that may reflect important functional differences. For instance, while over 50 mutations have been identified in PS1, only two mutations have been found in PS2 that are definitively linked to FAD: one in a group of eight Volga German kindreds (PS2N141I) and another in an Italian kindred (PS2M239V) (5, 6). In addition, PS1 mutations cause an aggressive form of FAD with a particularly early age of onset, whereas PS2 is associated with a form of FAD that more closely resembles sporadic AD in terms of age of onset and disease duration (7). Physiologically, although PS1 and PS2 share in common certain features such as modulating Abeta production, there are also key distinctions. Regarding their effect on apoptosis, for example, wild-type PS2 (wtPS2), but not PS1, has been shown to be proapoptotic (8-10). In addition, PS1 and PS2 exhibit contrasting roles in affecting neuronal differentiation in vitro (11). Therefore, the functions mediated by the presenilins cannot be assumed to be identical.

PS1 mutations alter intracellular calcium signaling pathways in a variety of experimental systems (10, 12-19). These changes may be highly relevant to the pathogenesis of AD, since calcium dysregulation can contribute to several key features of AD, including increased Abeta production (20, 21), hyperphosphorylation of tau (22), enhanced vulnerability to cell death (10, 23), and even memory-related deficits (24). However, despite the likely significance of these changes to the pathogenesis of AD, no studies have yet reported the effects of PS2 mutations on calcium signaling.

Circumstantial experimental evidence supports the potential involvement of PS2 in intracellular calcium regulation. For instance, PS2 interacts with a calcium-binding protein, calsenilin, that has been shown to regulate the levels of the caspase-3 cleavage product of PS2 (25). Although the function of calsenilin remains to be determined, sequence homology with neuronal calcium sensor-1 suggests that it may play a role in regulating intracellular calcium levels. Moreover, PS2, but not PS1, interacts with another calcium-binding protein known as sorcin (26). Sorcin is known to modulate the activity of ryanodine receptors (27), a major type of intracellular calcium release channel, and has also been found to associate with L-type voltage-gated calcium channels (28). Collectively, these findings suggest a possible physiological role for PS2 in regulating calcium signaling pathways, a function that may be modulated by FAD mutations.

Here we studied the effects of wild-type PS2 (wtPS2) and both of the identified FAD-linked PS2 mutations on calcium signaling in Xenopus oocytes. We show that, relative to controls, both FAD mutations in PS2 significantly potentiated calcium signals evoked by the ubiquitous intracellular second messenger inositol 1,4,5-trisphosphate (IP3). Notably, both PS2 mutations also significantly accelerated decay rates of calcium signals evoked by high levels of IP3. These findings lend strong support to the hypothesis that alterations in calcium signaling pathways may be a common pathogenic mechanism by which presenilin mutations contribute to FAD.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

cRNA Synthesis and Injection-- Full-length cDNAs encoding human wtPS2, PS2NI141I, and PS2M239V were the generous gift of Dr. John Hardy. Synthesis of m7G(5')ppp(5')G-capped cRNA was performed by run-off transcription of template plasmids linearized with the restriction endonuclease XbaI using the Riboprobe Gemini System (Promega) according to manufacturer's recommendations. The quantity and quality of the resulting transcripts were determined by spectrophotometric analysis and direct visualization on a denaturing gel as described elsewhere (17). Stage V and VI oocytes of Xenopus laevis (Xenopus I, Ann Arbor, MI) were defolliculated by two 1-h treatments with 0.5 mg/ml collagenase and were injected the following day with 46 nl of the appropriate cRNA (500 ng/µl) or RNase-free H2O (17).

Injection with Calcium Indicator and Caged IP3-- Three days after cRNA injection and 1-4 h prior to calcium imaging experiments, oocytes were loaded with 46 nl of a mixture containing 0.25 mM caged IP3 (c-IP3; D-myo-inositol 1,4,5-trisphosphate, P4(5)-(1-(2-nitrophenyl)ethyl) ester; Molecular Probes, Eugene, OR) and 1 mM of the low affinity calcium indicator Oregon Green-5N (OG-5N; Molecular Probes), yielding final concentrations in the oocytes of ~12 and ~46 µM, respectively. To ensure equal loading of the oocytes, we used a piston-driven Nanoject microinjector apparatus (Drummond Scientific) fitted with freshly pulled glass electrodes with tip diameters of ~15-20 µm.

Photolysis of c-IP3 and Calcium Imaging-- Photolysis of c-IP3 to liberate free intracellular IP3 was achieved using flashes of UV light (340-400 nm) derived from a mercury arc lamp (17). The concentration of IP3 photoreleased by UV light is a function of both flash duration, controlled by a mechanical shutter, and flash intensity, controlled by a neutral density filter (29). For experiments using supramaximal IP3 stimulation, the neutral density filter was reduced so that further increases in UV intensity failed to generate increased calcium signals in response to a fixed (200 ms) flash duration. Remaining experiments used a neutral density setting giving a flash intensity ~57-fold weaker. Estimates of IP3 concentrations (see legend to Fig. 2) were calculated based on previous findings indicating that ~50 nM IP3 is required to initiate a calcium wave (29).

Calcium-dependent fluorescence changes of OG-5N in response to photoreleased IP3 were imaged using a custom-built line-scanning confocal microscope, and data were recorded and analyzed as described previously (30). Fluorescence intensities were averaged over a 50-µm scan line and are expressed as the change in intensity over the basal level of fluorescence prior to stimulation (Delta F/Fo). Statistical comparisons were made using two-factor analysis of variance with replication. All results are presented as mean values ± S.E.

Western Blotting-- Immediately following completion of the calcium imaging experiments, cells were frozen for later processing. Protein extracts were prepared as described previously (17) and concentrations determined by the Bradford method. Equal amounts of protein (10 µg) were separated by SDS-polyacrylamide gel electrophoresis on 5 or 10% acrylamide gels, transferred to nitrocellulose membranes, blocked overnight in 5% non-fat milk in Tris-buffered saline (pH 7.5) supplemented with 0.2% Tween 20, and processed as described previously (17). The alpha PS2N antibody (the generous gift of Dr. Carl Cotman) was generated in rabbits by immunization with a synthetic peptide corresponding to amino acids 8-21 of the PS2 protein, affinity-purified, and used at a dilution of 1:1000. Other antibodies and dilutions used in this study include PS2NT (1:5000; the generous gift of Dr. Gopal Thinakaran; Ref. 31); PS2 loop antibody 3711 (1:500; the generous gift of Dr. Christian Haass; Ref. 32); and alpha IP3R-I, a rabbit polyclonal anti-type-I IP3 receptor antibody (Affinity Bioreagents, Golden, CO). Quantitative densitometric analyses were performed on digitized images of immunoblots using the Stratagene EagleEye II gel documentation system according to manufacturer's recommendations (Stratagene, La Jolla, CA).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

IP3-mediated Calcium Release Is Potentiated by PS2 Mutations-- To determine whether PS2 mutations modulate IP3-mediated calcium signaling, we conducted fluorescent calcium imaging in Xenopus oocytes expressing wild-type or mutant PS2 and H2O-injected controls (Fig. 1). Intracellular IP3 was liberated from a caged precursor by flashes of UV light. By varying the flash durations, different relative amounts of IP3 could be photoreleased in a reproducible manner. The rapid calcium signals evoked by photorelease of caged IP3 are almost exclusively due to liberation of calcium from the ER through IP3 receptors and negligible amounts of calcium influx from outside the cell occur at this time scale (33).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 1.   PS2 mutations potentiate IP3-evoked calcium liberation. A, sample recordings of calcium-dependent OG-5N fluorescence changes evoked by photoreleased IP3 in single oocytes injected 3 days prior to recording with either H2O or 25 ng of cRNA encoding either wtPS2, PS2N141I, or PS2M239. Superimposed traces show responses evoked by 20-, 60-, and 120-ms flash durations, expressed as the change in fluorescence intensity relative to baseline (Delta F/Fo). Arrowheads indicate approximate time of flash onset. Note that responses elicited by 120-ms flashes (bold) are markedly accelerated in mutant PS2-expressing cells, but not in wtPS2-expressing cells or controls, relative to signals evoked by shorter flash durations. B, mean peak Delta F/Fo plotted as a function of flash duration (i.e. [IP3]) in control cells (open circle ), or cells expressing wtPS2 (), PS2N141I (), or PS2M239V (black-triangle) (n = 8-10 oocytes per condition taken from a single donor frog). C, quantitative comparison of mean peak Delta F/Fo in response to maximal IP3 stimulation in cells expressing each of the PS2 constructs or controls (n = 28-30 cells per condition from two donor frogs). All values represent means ± S.E., although S.E. values were omitted where data were not normally distributed; *, p < 0.05 relative to H2O-injected controls; **, p < 0.001 relative to H2O-injected controls and p < 0.05 relative to wtPS2-expressing cells.

Relative to controls, cells expressing either PS2N141I or PS2M239V exhibited larger mean peak responses for each flash duration tested, whereas wtPS2-expressing cells produced responses intermediate between mutant-expressing and control cells (Fig. 1, A and B). Moreover, with increasing flash duration, mean peak calcium responses approached higher asymptotic maxima in mutant PS2-expressing cells relative to controls (e.g. for 120-ms flashes, Delta F/Fo = 1.40 ± 0.08 versus 0.93 ± 0.06 for PS2N141I-injected cells versus controls, respectively; p < 0.001; Fig. 1B). To ensure that absolute maximal levels of IP3-mediated calcium release had been achieved, cells were further stimulated with supramaximal [IP3] (~30 µM; see "Experimental Procedures"). As with lower stimulus intensities, mean peak calcium responses following supramaximal IP3 stimulation were significantly increased in cells expressing PS2 mutations relative both to wtPS2-expressing cells and to controls (Fig. 1C). Therefore, PS2 mutations consistently increase the mean amplitude of calcium responses evoked by a wide range of IP3 levels.

The threshold for IP3-mediated calcium release was lower in cells expressing PS2 mutations relative to controls, since we found that mutant-expressing cells responded more frequently than controls to the lowest flash durations tested. For example, in response to flash durations of 20 ms, six out of nine cells expressing PS2N141I responded as compared with only 1 of 10 H2O-injected controls (p < 0.001 by chi 2 analysis). PS2M239V-expressing cells displayed even more marked differences, being the only cells to respond to flash durations of 10 ms (2 out of 10 trials; see Fig. 1B). Taken together, these data suggest that PS2 mutations confer an increased sensitivity to IP3.

PS2 Mutations Accelerate Decay Rates of Calcium Signals-- We also examined the effects of PS2 mutations on the decay rates of calcium signals evoked by different concentrations of IP3, which were quantitated by measuring the half-decay time (t1/2) of individual signals (Fig. 2). At low [IP3] (~0.15 µM; see "Experimental Procedures"), calcium responses in wild-type and mutant PS2-expressing cells and controls decayed at similar rates (Fig. 2, A and B). By comparison, following supramaximal IP3 stimulation ("high [IP3]"; ~30 µM), decay rates were significantly slowed in wtPS2-expressing cells and controls (which were not significantly different from each other; Fig. 2, C and D). In striking contrast, decay rates were significantly accelerated in mutant PS2-expressing cells following supramaximal IP3 stimulation relative to wtPS2-expressing cells and controls (Fig. 2, C and D; see also bold traces in Fig. 1A).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 2.   PS2 mutations accelerate decay rates of calcium signals evoked by high, but not low, [IP3]. A and C, average calcium responses evoked by "low [IP3]" (A; ~0.15 µM) or "high [IP3]" (C; ~30 µM) in cells expressing either wtPS2, PS2N141I, or PS2M239V. Traces represent the averages of 10 responses per condition, that have been normalized and superimposed for comparison. B and D, quantitation of mean times to decay from peak Delta F/Fo to one-half peak (t1/2) for all recordings (n = 28-30 per condition) following stimulation with low or high [IP3], respectively. Note that decay rates of calcium signals in mutant PS2-expressing cells are accelerated at high, but not low, [IP3]; wtPS2-expressing cells did not differ significantly from controls. *, p < 0.05 relative to H2O-injected controls; **, p < 0.001 relative to H2O-injected controls and p < 0.05 relative to PS2N141I-expressing cells.

Expression of PS2 and IP3 Receptor Proteins-- To ascertain if differences in calcium signaling were due to differences in PS2 expression levels, protein extracts from the oocytes used for calcium imaging experiments were subjected to Western analysis using several anti-PS2 antibodies (Fig. 3A). For each antibody tested, protein expression levels did not differ by more than 5% among the PS2 cRNA-injected conditions, as determined by densitometric analysis. Therefore, the increased potentiation observed in mutant PS2-expressing cells relative to wild-type PS2-expressing cells is not attributable to differences in protein expression levels. Interestingly, some antibodies, including the alpha PS2N antibody (Fig. 3A), also detected a weak band in the H2O-injected controls, presumably reflecting endogenous Xenopus presenilin (34).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 3.   Potentiation of calcium signaling is not attributable to differences in PS2 or IP3 receptor protein expression levels. Immunoblots of protein extracts from control cells and cells injected with wtPS2 or PS2N141I or PS2M239V cRNA. A, representative immunoblot of PS2 protein levels using antibody alpha PS2N: levels of PS2 protein did not differ by more than 5% as determined by densitometric analysis. Similar results were obtained using several other well characterized anti-PS2 antibodies (see "Experimental Procedures"). Note the presence of a faint band in the H2O-injected cells which may represent Xenopus presenilin. B, levels of type-I IP3 receptors detected with antibody alpha IP3R-I (Affinity Bioreagents). Protein levels differed only slightly (<7%), and these differences do not correlate with differences in mean amplitudes of calcium signals exhibited by cells in the various conditions.

To address the mechanism by which PS2 mutations potentiate IP3-mediated calcium release, we also conducted a Western analysis of type-I IP3 receptors (Fig. 3B), which are the only type of calcium release channel expressed in Xenopus oocytes (35). IP3 receptor protein levels differed only slightly (~7%) between control cells and cells expressing wild-type or mutant PS2, and these small differences did not correlate consistently with the amplitudes of calcium responses in the various conditions. These findings indicate that mechanisms other than IP3 receptor up-regulation are responsible for the observed potentiation in IP3-mediated calcium signaling.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The "calcium hypothesis" of AD proposes that perturbed intracellular calcium homeostasis plays a central role in AD neurodegeneration (36). In support of the idea, several distinct AD-linked PS1 mutations have been shown to modulate calcium signaling in a variety of systems, including fibroblasts from FAD patients (12, 15, 16), mutant PS1 "knock-in" mice (18), transgenic mice (19), transfected PC-12 cells (10, 14), and Xenopus oocytes (17). However, to our knowledge, the effects of PS2 mutations on calcium signaling have not previously been examined. We addressed this question by measuring IP3-mediated calcium signals in Xenopus oocytes expressing wild-type PS2 and the two identified FAD-linked mutations in PS2. Calcium signals were potentiated in oocytes overexpressing wild-type PS2 as compared with H2O-injected controls, and a further potentiation was observed in oocytes expressing similar amounts of mutant PS2. Notably, the nature and extent of this potentiation closely resembles the results we observed for mutant PS1 using identical methods in the same system (17). Therefore, FAD mutations in both PS1 and PS2 lead to similar alterations in IP3-mediated calcium signaling, providing further evidence that intracellular calcium dysregulation may represent a common pathophysiological consequence of all AD-linked presenilin mutations. Since elevated cytosolic calcium levels can lead to several hallmark features of AD, including increased levels of Abeta (20, 21), hyperphosphorylated tau (22), and enhanced susceptibility to cell death (10, 23), these findings lend additional support to the hypothesis that calcium dysregulation plays a causative role in the pathogenesis of AD. Conversely, our data do not reveal differences in IP3-mediated calcium signaling that may account for the contrasting functional differences between the PS1 and PS2 proteins.

Oocytes expressing wild-type PS2 exhibited potentiated IP3-mediated calcium release relative to H2O-injected controls, albeit to a lesser extent than those expressing the FAD mutations. Overexpression of wild-type PS1 in the same system also produced a comparable potentiation in IP3-mediated calcium release (17). Although the significance of these findings is not presently clear, these results may reflect a physiological function of endogenous presenilins in calcium signaling, a function that is perturbed by FAD mutations. Given the interaction of the presenilins with calsenilin (25), which is homologous to proteins involved in calcium homeostasis, and sorcin, which modulates calcium release through ryanodine receptors, this possibility warrants further investigation.

Although the mechanism by which PS2 mutations potentiate IP3-mediated calcium signaling remains to be established, up-regulation of IP3 receptors does not appear to be involved, since comparable levels of IP3 receptor levels were present in control cells and in cells expressing wild-type and mutant PS2. Alternative possibilities may involve alteration of IP3-receptor function or overfilling of the ER calcium pools. In support of the latter idea, measurements of store content obtained by using thapsigargin to release calcium show an enhancement in PC-12 cells expressing mutant PS1 (14).

Rates of decay of calcium signals evoked by supramaximal [IP3] were also markedly accelerated by PS2 mutations. The decay of the fluorescent calcium signal represents a balance between calcium efflux through activated IP3 receptors and mechanisms that remove calcium ions from the cytosol (e.g. reuptake into the ER, uptake into mitochondria, extrusion across plasma membrane). Although we cannot entirely exclude effects of PS2 mutations on calcium sequestration mechanisms, it seems unlikely that this could result in an acceleration of calcium transport at high, but not low, [IP3]. One mechanism that may account for these results might be an increase in the rate of inactivation of IP3 receptors in the presence of high [IP3]. Alternatively, the accelerated decay rates might be due to the increased calcium release evoked by high [IP3] in the mutant PS2-expressing cells, since it is known that high local levels of cytosolic calcium can actually inhibit the opening of IP3 receptors (37).

The fact that intracellular calcium signaling is modulated by mutations in both PS1 and PS2 increases support for the hypothesis that these disturbances play a causative role in the pathogenesis of FAD. In view of the central importance of intracellular calcium regulation for numerous cellular processes, elucidation of the mechanisms responsible for these changes is clearly warranted and could uncover novel targets for therapeutic intervention.

    ACKNOWLEDGEMENTS

We thank Drs. Carl Cotman, Christian Haass, and Gopal Thinakaran for providing us with PS2 antibodies, Dr. John Hardy for the PS2 cDNAs, Alan Dakak for technical assistance, and Drs. Nicholas Callamaras and Jonathan Marchant for technical advice.

    FOOTNOTES

* This work was supported by a grant from the University of California Irvine-Markey Program in Human Neurobiology (to F. M. L.), Grant GM-48071 (to I. P.), and a scholarship from the Glenn Foundation/American Federation for Aging Research (awarded to M. A. L.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed: Dept. of Neurobiology & Behavior, University of California, Irvine, 1109 Gillespie Neuroscience Facility, Irvine, CA 92697-4545. Tel.: 949-824-1232; Fax: 949-824-7356; E-mail: laferla@uci.edu.

    ABBREVIATIONS

The abbreviations used are: FAD, familial Alzheimer's disease; AD, Alzheimer's disease; c-IP3, caged IP3; ER, endoplasmic reticulum; IP3, inositol 1,4,5-trisphosphate; PS1 and PS2, presenilin-1 and presenilin-2; OG-5N, Oregon green-5N.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Cruts, M., van Duijn, C. M., Backhovens, H., Van den Broeck, M., Wehnert, A., Serneels, S., Sherrington, R., Hutton, M., Hardy, J., St George-Hyslop, P. H., Hofman, A., and Van Broeckhoven, C. (1998) Hum. Mol. Genet. 7, 43-51[Abstract/Free Full Text]
2. Kovacs, D. M., Fausett, H. J., Page, K. J., Kim, T. W., Moir, R. D., Merriam, D. E., Hollister, R. D., Hallmark, O. G., Mancini, R., Felsenstein, K. M., Hyman, B. T., Tanzi, R. E., and Wasco, W. (1996) Nat. Med. 2, 224-229[CrossRef][Medline] [Order article via Infotrieve]
3. Zhang, J., Kang, D. E., Xia, W., Okochi, M., Mori, H., Selkoe, D. J., and Koo, E. H. (1998) J. Biol. Chem. 273, 12436-12442[Abstract/Free Full Text]
4. Cribbs, D. H., Chen, L. S., Bende, S. M., and LaFerla, F. M. (1996) Am. J. Pathol. 148, 1797-1806[Abstract]
5. Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C. E., Jondro, P. D., Schmidt, S. D., Wang, K., et al.. (1995) Science 269, 973-977[Abstract/Free Full Text]
6. Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al.. (1995) Nature 376, 775-778[CrossRef][Medline] [Order article via Infotrieve]
7. Renbaum, P., and Levy-Lahad, E. (1998) Cell. Mol. Life Sci. 54, 910-919[CrossRef][Medline] [Order article via Infotrieve]
8. Vito, P., Wolozin, B., Ganjei, J. K., Iwasaki, K., Lacana, E., and D'Adamio, L. (1996) J. Biol. Chem. 271, 31025-31028[Abstract/Free Full Text]
9. Deng, G., Pike, C. J., and Cotman, C. W. (1996) FEBS Lett 397, 50-54[CrossRef][Medline] [Order article via Infotrieve]
10. Guo, Q., Sopher, B. L., Furukawa, K., Pham, D. G., Robinson, N., Martin, G. M., and Mattson, M. P. (1997) J. Neurosci. 17, 4212-4222[Abstract/Free Full Text]
11. Hong, C. S., Caromile, L., Nomata, Y., Mori, H., Bredesen, D. E., and Koo, E. H. (1999) J. Neurosci. 19, 637-643[Abstract/Free Full Text]
12. Ito, E., Oka, K., Etcheberrigaray, R., Nelson, T. J., McPhie, D. L., Tofel-Grehl, B., Gibson, G. E., and Alkon, D. L. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 534-538[Abstract/Free Full Text]
13. Gibson, G. E., Zhang, H., Toral-Barza, L., Szolosi, S., and Tofel-Grehl, B. (1996) Biochim. Biophys. Acta 1316, 71-77[Medline] [Order article via Infotrieve]
14. Guo, Q., Furukawa, K., Sopher, B. L., Pham, D. G., Xie, J., Robinson, N., Martin, G. M., and Mattson, M. P. (1996) Neuroreport 8, 379-383[Medline] [Order article via Infotrieve]
15. Gibson, G. E., Vestling, M., Zhang, H., Szolosi, S., Alkon, D., Lannfelt, L., Gandy, S., and Cowburn, R. F. (1997) Neurobiol. Aging 18, 573-580[CrossRef][Medline] [Order article via Infotrieve]
16. Etcheberrigaray, R., Hirashima, N., Nee, L., Prince, J., Govoni, S., Racchi, M., Tanzi, R. E., and Alkon, D. L. (1998) Neurobiol. Dis. 5, 37-45[CrossRef][Medline] [Order article via Infotrieve]
17. Leissring, M. A., Paul, B. A., Parker, I., Cotman, C. W., and LaFerla, F. M. (1999) J. Neurochem. 72, 1061-1068[CrossRef][Medline] [Order article via Infotrieve]
18. Guo, Q., Fu, W., Sopher, B. L., Miller, M. W., Ware, C. B., Martin, G. M., and Mattson, M. P. (1999) Nat. Med. 5, 101-106[CrossRef][Medline] [Order article via Infotrieve]
19. Begley, J. G., Duan, W., Chan, S., Duff, K., and Mattson, M. P. (1999) J. Neurochem. 72, 1030-1039[CrossRef][Medline] [Order article via Infotrieve]
20. Querfurth, H. W., and Selkoe, D. J. (1994) Biochemistry 33, 4550-4561[CrossRef][Medline] [Order article via Infotrieve]
21. Querfurth, H. W., Jiang, J., Geiger, J. D., and Selkoe, D. J. (1997) J. Neurochem. 69, 1580-1591[Medline] [Order article via Infotrieve]
22. Mattson, M. P., Engle, M. G., and Rychlik, B. (1991) Mol. Chem. Neuropathol. 15, 117-142[Medline] [Order article via Infotrieve]
23. Mattson, M. P., Guo, Q., Furukawa, K., and Pedersen, W. A. (1998) J. Neurochem. 70, 1-14[Medline] [Order article via Infotrieve]
24. Disterhoft, J. F., Moyer, J. R., Jr., and Thompson, L. T. (1994) Ann. N. Y. Acad. Sci. 747, 382-406[Medline] [Order article via Infotrieve]
25. Buxbaum, J. D., Choi, E. K., Luo, Y., Lilliehook, C., Crowley, A. C., Merriam, D. E., and Wasco, W. (1998) Nat. Med. 4, 1177-1181[CrossRef][Medline] [Order article via Infotrieve]
26. Kim, T.-W., Pettingell, W. P., and Tanzi, R. E. (1998) Soc. Neurosci. Abstr. 24, 757
27. Meyers, M. B., Pickel, V. M., Sheu, S. S., Sharma, V. K., Scotto, K. W., and Fishman, G. I. (1995) J. Biol. Chem. 270, 26411-26418[Abstract/Free Full Text]
28. Meyers, M. B., Puri, T. S., Chien, A. J., Gao, T., Hsu, P. H., Hosey, M. M., and Fishman, G. I. (1998) J. Biol. Chem. 273, 18930-18935[Abstract/Free Full Text]
29. Callamaras, N., and Parker, I. (1998) Methods Enzymol. 291, 380-403[Medline] [Order article via Infotrieve]
30. Sun, X. P., Callamaras, N., Marchant, J. S., and Parker, I. (1998) J. Physiol. (Lond.) 509, 67-80[Abstract/Free Full Text]
31. Saura, C. A., Tomita, T., Davenport, F., Harris, C. L., Iwatsubo, T., and Thinakaran, G. (1999) J. Biol. Chem. 274, 13818-13823[Abstract/Free Full Text]
32. Walter, J., Grunberg, J., Schindzielorz, A., and Haass, C. (1998) Biochemistry 37, 5961-5967[CrossRef][Medline] [Order article via Infotrieve]
33. Yao, Y., and Parker, I. (1993) J. Physiol. (Lond.) 468, 275-295[Abstract/Free Full Text]
34. Tsujimura, A., Yasojima, K., and Hashimoto-Gotoh, T. (1997) Biochem. Biophys. Res. Commun. 231, 392-396[CrossRef][Medline] [Order article via Infotrieve]
35. Kume, S., Muto, A., Aruga, J., Nakagawa, T., Michikawa, T., Furuichi, T., Nakade, S., Okano, H., and Mikoshiba, K. (1993) Cell 73, 555-570[CrossRef][Medline] [Order article via Infotrieve]
36. Khachaturian, Z. S. (1987) Neurobiol. Aging 8, 345-346[CrossRef][Medline] [Order article via Infotrieve]
37. Bezprozvanny, I., Watras, J., and Ehrlich, B. E. (1991) Nature 351, 751-754[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.



This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
Y. S. Oh and R. J. Turner
Effect of {gamma}-secretase inhibitors on muscarinic receptor-mediated calcium signaling in human salivary epithelial cells
Am J Physiol Cell Physiol, July 1, 2006; 291(1): C76 - C82.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
D. G. Cook, X. Li, S. D. Cherry, and A. R. Cantrell
Presenilin 1 Deficiency Alters the Activity of Voltage-Gated Ca2+ Channels in Cultured Cortical Neurons
J Neurophysiol, December 1, 2005; 94(6): 4421 - 4429.
[Abstract] [Full Text] [PDF]


Home page
NeuroscientistHome page
G. E. Stutzmann
Calcium Dysregulation, IP3 Signaling, and Alzheimer's Disease
Neuroscientist, April 1, 2005; 11(2): 110 - 115.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
C. M. P. Ribeiro, A. M. Paradiso, M. A. Carew, S. B. Shears, and R. C. Boucher
Cystic Fibrosis Airway Epithelial Ca2+i Signaling: THE MECHANISM FOR THE LARGER AGONIST-MEDIATED Ca2+i SIGNALS IN HUMAN CYSTIC FIBROSIS AIRWAY EPITHELIA
J. Biol. Chem., March 18, 2005; 280(11): 10202 - 10209.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Kitagawa, S. Shimohama, T. Oeda, K. Uemura, R. Kohno, A. Kuzuya, H. Shibasaki, and N. Ishii
The Role of the Presenilin-1 Homologue Gene sel-12 of Caenorhabditis elegans in Apoptotic Activities
J. Biol. Chem., March 28, 2003; 278(14): 12130 - 12134.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Morohashi, N. Hatano, S. Ohya, R. Takikawa, T. Watabiki, N. Takasugi, Y. Imaizumi, T. Tomita, and T. Iwatsubo
Molecular Cloning and Characterization of CALP/KChIP4, a Novel EF-hand Protein Interacting with Presenilin 2 and Voltage-gated Potassium Channel Subunit Kv4
J. Biol. Chem., April 19, 2002; 277(17): 14965 - 14975.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. A. Leissring, M. P. Murphy, T. R. Mead, Y. Akbari, M. C. Sugarman, M. Jannatipour, B. Anliker, U. Muller, P. Saftig, B. De Strooper, et al.
A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP
PNAS, March 21, 2002; (2002) 72033799.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
A. L. Mah, G. Perry, M. A. Smith, and M. J. Monteiro
Identification of Ubiquilin, a Novel Presenilin Interactor That Increases Presenilin Protein Accumulation
J. Cell Biol., November 13, 2000; 151(4): 847 - 862.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. A. Leissring, T. R. Yamasaki, W. Wasco, J. D. Buxbaum, I. Parker, and F. M. LaFerla
Calsenilin reverses presenilin-mediated enhancement of calcium signaling
PNAS, July 18, 2000; 97(15): 8590 - 8593.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
M. A. Leissring, Y. Akbari, C. M. Fanger, M. D. Cahalan, M. P. Mattson, and F. M. LaFerla
Capacitative Calcium Entry Deficits and Elevated Luminal Calcium Content in Mutant Presenilin-1 Knockin Mice
J. Cell Biol., May 15, 2000; 149(4): 793 - 798.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Pack-Chung, M. B. Meyers, W. P. Pettingell, R. D. Moir, A. M. Brownawell, I. Cheng, R. E. Tanzi, and T.-W. Kim
Presenilin 2 Interacts with Sorcin, a Modulator of the Ryanodine Receptor
J. Biol. Chem., May 5, 2000; 275(19): 14440 - 14445.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. A. Leissring, M. P. Murphy, T. R. Mead, Y. Akbari, M. C. Sugarman, M. Jannatipour, B. Anliker, U. Muller, P. Saftig, B. De Strooper, et al.
A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP
PNAS, April 2, 2002; 99(7): 4697 - 4702.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leissring, M. A.
Right arrow Articles by LaFerla, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leissring, M. A.
Right arrow Articles by LaFerla, F. M.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.